Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1653lxm

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

********** Welcome to STN International **********

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 Feb 24 PCTGEN now available on STN
NEWS 4 Feb 24 TEMA now available on STN
NEWS 5 Feb 26 NTIS now allows simultaneous left and right truncation
NEWS 6 Feb 26 PCTFULL now contains images
NEWS 7 Mar 04 SDI PACKAGE for monthly delivery of multifile SDI results
NEWS 8 Mar 24 PATDPAFULL now available on STN
NEWS 9 Mar 24 Additional information for trade-named substances without structures available in REGISTRY
NEWS 10 Apr 11 Display formats in DGENE enhanced
NEWS 11 Apr 14 MEDLINE Reload
NEWS 12 Apr 17 Polymer searching in REGISTRY enhanced
NEWS 13 Jun 13 Indexing from 1947 to 1956 added to records in CA/CAPLUS
NEWS 14 Apr 21 New current-awareness alert (SDI) frequency in WPIDS/WPINDEX/WPIX
NEWS 15 Apr 28 RDISCLOSURE now available on STN
NEWS 16 May 05 Pharmacokinetic information and systematic chemical names added to PHAR
NEWS 17 May 15 MEDLINE file segment of TOXCENTER reloaded
NEWS 18 May 15 Supporter information for ENCOMPPAT and ENCOMPLIT updated
NEWS 19 May 19 Simultaneous left and right truncation added to WSCA
NEWS 20 May 19 RAPRA enhanced with new search field, simultaneous left and right truncation
NEWS 21 Jun 06 Simultaneous left and right truncation added to CBNB
NEWS 22 Jun 06 PASCAL enhanced with additional data
NEWS 23 Jun 20 2003 edition of the FSTA Thesaurus is now available
NEWS 24 Jun 25 HSDB has been reloaded
NEWS 25 Jul 16 Data from 1960-1976 added to RDISCLOSURE
NEWS 26 Jul 21 Identification of STN records implemented
NEWS 27 Jul 21 Polymer class term count added to REGISTRY
NEWS 28 Jul 22 INPADOCDB Basic index (BI) enhanced; Simultaneous Left and Right Truncation available

NEWS EXPRESS April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

********** STN Columbus **********

FILE 'HOME' ENTERED AT 18:27:19 ON 31 JUL 2003

> file registry

COST IN U.S. DOLLARS	ENTRY	SINCE FILE SESSION	TOTAL
FULL ESTIMATED COST		0.21	0.21

FILE 'REGISTRY' ENTERED AT 18:27:33 ON 31 JUL 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 30 JUL 2003 HIGHEST RN 557744-74-8
DICTIONARY FILE UPDATES: 30 JUL 2003 HIGHEST RN 557744-74-8

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

```
> s sns/sqep
        0 SNS/SQEP
     1461 SQL=3
L1      0 SNS/SQEP
          (SNS/SQEP AND SQL=3)

> s sqs/sqep
        0 SQS/SQEP
     1461 SQL=3
L2      0 SQS/SQEP
          (SQS/SQEP AND SQL=3)

> s snt/sqep or snc/sqep
        0 SNT/SQEP
     1461 SQL=3
        0 SNT SQEP
          (SNT SQEP AND SQL=3)
        0 SNC SQEP
     1461 SQL=3
        0 SNC SQEP
          (SNC SQEP AND SQL=3)
L3      0 SNT SQEP OR SNC SQEP

> s sqt or sqe sqep
```

'BP' NOT VALID IN A SEQUENCE QUERY
The field code specified is not valid in a sequence query. For more information, enter "HELP SSQ" at an arrow prompt ( ).

? s sqt/sqep or sqc/sqep
0 SQT/SQEP
1461 SQL=3
0 SQT/SQEP
(SQT/SQEP AND SQL=3)
0 SQC/SQEP
1461 SQL=3
0 SQC/SQEP
(SQC/SQEP AND SQL=3)
L4 0 SQT/SQEP OR SQC/SQEP

? s tns/sqep or tnt/sqep or tnc/sqep or tqs/sqep or tqt/sqep or tqc/sqep
4 TNS/SQEP
1461 SQL=3
4 TNS/SQEP
(TNS/SQEP AND SQL=3)
1 TNT/SQEP
1461 SQL=3
1 TNT/SQEP
(TNT/SQEP AND SQL=3)
1 TNC/SQEP
1461 SQL=3
1 TNC/SQEP
(TNC/SQEP AND SQL=3)
0 TQS/SQEP
1461 SQL=3
0 TQS/SQEP
(TQS/SQEP AND SQL=3)
0 TQT/SQEP
1461 SQL=3
0 TQT/SQEP
(TQT/SQEP AND SQL=3)
0 TQC/SQEP
1461 SQL=3
0 TQC/SQEP
(TQC/SQEP AND SQL=3)
L5 6 TNS/SQEP OR TNT/SQEP OR TNC/SQEP OR TQS/SQEP OR TQT/SQEP OR TQC/SQEP

? s cns/sqep or cnt/sqep or cnc/sqep or cqs/sqep or cqt/sqep or cqc/sqep
6 CNS/SQEP
1461 SQL=3
6 CNS/SQEP
(CNS/SQEP AND SQL=3)
0 CNT/SQEP
1461 SQL=3
0 CNT/SQEP
(CNT/SQEP AND SQL=3)
0 CNC/SQEP
1461 SQL=3
0 CNC/SQEP
(CNC/SQEP AND SQL=3)
0 CQS/SQEP
1461 SQL=3
0 CQS/SQEP
(CQS/SQEP AND SQL=3)
4 CQT/SQEP
1461 SQL=3

4 CQT SQEP
(CQT SQEP AND SQL 3)
0 CQC SQEP
1461 SQL 3
0 CQC SQEP
(CQC SQEP AND SQL 3)
L6 10 CNS SQEP OR CNT SQEP OR CNC SQEP OR CQS SQEP OR CQT SQEP OR CQC SQEP

> s l5 or l6
L7 16 L5 OR L6

> file caplus
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 116.20 116.41

FILE 'CAPLUS' ENTERED AT 18:31:36 ON 31 JUL 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 31 Jul 2003 VOL 139 ISS 5
FILE LAST UPDATED: 30 Jul 2003 (20030730/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l7
L8 9 L7

> d l8 1-9 all

L8 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2000:464012 CAPLUS
DN 133:101469
TI Calcitonin receptor-binding radiolabeled peptides as radiodiagnostic or radiotherapeutic agents
IN Dean, Richard T.; Bush, Larry R.; Pearson, Daniel A.; Lister-James, John
PA Diatide, Inc., USA
SO U.S., 25 pp., Cont.-in-part of U.S. Ser. No. 847,007.
CODEN: USXXAM
DT Patent
LA English
IC ICM A61K051-00
ICS A61M036-14
NCL 424001690
CC 8-9 (Radiation Biochemistry)
Section cross-reference(s): 63
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6086850	A	20000711	US 1998-71090	19980501
	US 6083480	A	20000704	US 1997-847007	19970501
	US 6479032	B1	20021112	US 2000-553493	20000420
	US 6509001	B1	20030121	US 2000-553494	20000420
PRAI	US 1997-847007	A2	19970501		
	US 1998-71090	A3	19980501		

OS MARPAT 133:101469

AB This invention relates to calcitonin receptor binding reagents comprising compds. which are covalently linked to a radiometal chelator. The invention is embodied as calcitonin receptor binding peptide derivs. and analogs of calcitonin which may be radiolabeled with a suitable isotope and used as radiodiagnostic or radiotherapeutic agents. Methods and kits for making, radiolabeling and using such reagents diagnostically and therapeutically in a mammalian body are also provided.

ST radiolabel peptide calcitonin receptor diagnostic

L8 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1997:141258 CAPLUS

DN 126:251379

TI Total synthesis of WS9326A, a potent tachykinin antagonist from Streptomyces violaceoniger

AU Shigematsu, Nobuharu; Kayakiri, Natsuko; Okada, Satoshi; Tanaka, Hirokazu

CS Exploratory Res. Labs., Fujisawa Pharmaceutical Co., Ltd., Ibaraki, 300-26, Japan

SO Chemical & Pharmaceutical Bulletin (1997), 45(2), 236-242
CODEN: CPBTAL; ISSN: 0009-2363

PB Pharmaceutical Society of Japan

DT Journal

LA English

CC 34-3 (Amino Acids, Peptides, and Proteins)

OS CASREACT 126:251379

GI

AB Total synthesis of the cyclic peptide lactone WS9326A (I), a potent tachykinin antagonist isolated from streptomyces violaceoniger strain 9326, has been achieved via Cbz-Thr[Boc-allo-Thr-Asn-Ser(CH2Ph)]-(E)-.DELTA.MeTyr-Leu-D-Phe-OCH2CCl3 [Boc = Me3CO2C; Cbz = PhCH2O2C; .DELTA.MeTyr = .alpha.,.beta.-dehydro-N-methyltyrosine] which was cyclized (Phe and allo-Thr) using an active ester method with N-hydroxysuccinimide. Finally the unique N-acyl group, the 2-[1(Z)-pentenyl]cinnamoyl moiety, was introduced onto the amino group in the Thr unit. The key step of the synthesis involves the prepn. of the (E)-.DELTA.MeTyr residue. The debenzoxylation reaction of threo- and erythro-.beta.-benzoxy-N-methyltyrosine derivs. gave exclusively Cbz-Thr-(Z)-.DELTA.MeTyr(CH2OMe)-OMe, which was then converted to the desired E-isomer by photochem. isomerization of Cbz-Thr(TBDMS)-(Z)-.DELTA.MeTyr(CH2OMe)-Leu-D-Phe-OCH2CCl3 at a later step.

ST total synthesis tachykinin antagonist WS9326A; dehydromethyltyrosine building block prepn isomerization; cyclic peptide lactone WS9326A prepn

IT 56-40-6, Glycine, reactions 112-76-5, Stearoyl chloride 123-08-0, 4-Hydroxybenzaldehyde 7536-55-2 13139-15-6 18942-49-9 19728-63-3, Z-Thr-OH 23082-30-6 23680-31-1 125775-13-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(total synthesis of potent tachykinin antagonist WS9326A from Streptomyces violaceoniger)

IT

L8 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1992:84187 CAPLUS

DN 116:84187

TI Manufacture of peptides WS-9320A and WS-9326B with Streptomyces

violaceoniger and chemical synthesis of these peptides and derivatives as analgesics

PA Fujisawa Pharmaceutical Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 54 pp.
CODEN: JKXXAF

DT Patent

LA Japanese

IC ICM A61K037-02

ICA C07K007-06

ICI C07K099-00

CC 34-3 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 1, 16

FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 03148227	A2	19910625	JP 1990-267946	19901004
US 5217952	A	19930608	US 1991-794698	19911120
US 5436140	A	19950725	US 1994-225915	19940411
PRAI US 1989-417470	A	19891005		
GB 1988-2229	A	19880202		
GB 1988-7921	A	19880405		
US 1989-304030	B2	19890131		
US 1989-333017	B2	19890404		
US 1991-794698	A3	19911120		
US 1992-987702	B3	19921209		

OS MARPAT 116:84187

GI

AB The title peptides [I; R1 = H, acyl; R2 = OH; R3 = (un)protected CO2H; or R2R3 = O2C; R4, R5 = (un)protected OH; R6 = (un)protected OH, alkoxy] are prepd. by the soln. method. Among these peptides 2 specific peptides WS-9320A (II; R = Q; Z = Q1) and WS-9326B II (R = Q, Z = MeTyr) (III) are also manufd. by fermn. of Streptomyces violaceoniger no. 9326. Thus, a soln. of 3.24 g HCl.H-Leu-D-Phe-allo-Thr(Bzl)-Asn-Ser(Bzl)-R [R = Z-Thr-MeTyr(Bzl)OH, forming an ester linkage with the serine residue through phenolic hydroxy group of tyrosine] (prepn. given), 350 .mu.L Et3N, and 6.11 g 1-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline in 1000 mL CH2Cl2 was stirred 24 h at room temp. to give, after hydrogenolysis over Pd in MeOH contg. HCO2H, II (R = H, X = MeTyr) which was acylated with a propenoyl chloride QCl (prepn. given) in pyridine to give III. I also have substance P-, neurokinin A-, neurokinin B-antagonizing activity and are useful for treatment of cardiovascular diseases, skin diseases, ulcers, and brain diseases. Tetrahydro-WS-9326A, i.e. II [R = 3-(2-pentylphenyl)propanoyl, Z = Q1] showed ED50 = 5.5 mg/kg i.p. in AcOH-induced rat writhing assay.

ST cyclic peptide prepn analgesic; WS9326A peptide Streptomyces violaceoniger; WS9326B peptide Streptomyces violaceoniger; substance P antagonist cyclic peptide; neurokinin A antagonist cyclic peptide

IT Nomenclature, new natural products

L8 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1990:139837 CAPLUS

DN 112:139837

TI Cyclic peptides WS-9326A and -B from Streptomyces violaceoniger and the derivatives of WS-9326A as antagonists of neurokinin A and substance P

IN Kino, Tohru; Nishikawa, Motoaki; Ezaki, Masami; Kiyoto, Sumio; Okuhara, Masakuni; Takase, Shigehiro; Okada, Satoshi; Shigematsu, Nobuharu

PA Fujisawa Pharmaceutical Co., Ltd., Japan

SO Eur. Pat. Appl., 106 pp.
CODEN: EPXXDW

DT Patent

LA English
IC ICM C07K007-06
ICS C12P021-02; C12P021-04; A61K037-02
ICI C12P021-02, C12R001-465; C12P021-04, C12R001-465
CC 34-3 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 1, 16
FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 336230	A2	19891011	EP 1989-105225	19890323
EP 336230	A3	19910717		
EP 336230	B1	19970212		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
ZA 8902188	A	19891129	ZA 1989-2188	19890322

PRAI GB 1988-7921 A 19880405
GB 1988-2229 A 19880202
US 1989-304030 B2 19890131
US 1989-333017 B2 19890404
US 1989-417470 B1 19891005
US 1991-794698 A3 19911120
US 1992-987702 B3 19921209
OS MARPAT 112:139837
GI

orR2R3 = OC(O); R4,R5 = (protected) OH; R6 = (protected) OH, alkoxy; dotted line = optional double bond], useful as substance K and substance P antagonists, were prepd. Thus, cyclic peptide II (R7 = Q) (WS-9326A), isolated from cultures of Streptomyces violaceoniger 9326, at 0.03 ng/kg intratracheally in guinea pigs gave 32-3% inhibition of neurokinin A-induced bronchoconstriction after 20 min. I were also prepd. synthetically.

ST peptideamide prepn substance P antagonist; neurokinin A antagonist peptideamide; WS9326A prepn bronchodilator; Streptomyces violaceoniger isolation peptide WS9326A

IT Streptomyces violaceoniger
(no. 9326, cyclic peptides WS9326A and -B from, isolation of, as antagonists of neurokinin A and substance P)

IT Peptides, preparation
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as antagonists of neurokinin A and substance P)

IT Bronchodilators

L8 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1989:108339 CAPLUS
DN 110:108339
TI Atrial natriuretic peptides cleaved by endopeptidase are inactive in conscious spontaneously hypertensive rats
AU Seymour, Andrea A.; Swerdel, Joel N.; Fennell, Susan A.; Delaney, Norma G.
CS Squibb Inst. Med. Res., Princeton, NJ, USA
SO Life Sciences (1988), 43(26), 2265-74
CODEN: LIFSAK; ISSN: 0024-3205
DT Journal
LA English
CC 2-2 (Mammalian Hormones)
AB The dose-related natriuretic and depressor responses to atrial natriuretic peptides (ANP) 99-126, 103-126, and 103-123 were detd. in unanesthetized spontaneously hypertensive rats (SHR) and were compared to the activities of their Cys105-Phe106 ring-opened metabolites. These metabolites were previously identified as the major initial products formed by incubation of the intact peptides with neutral endopeptidase (NEP). The areas over the curves (AOC) of the depressor responses to the intact peptides were

dose-related and, at 30 nmole/kg, i.v., were greatest for ANP 99-126 and 103-126 (833 and 1157 mmHg .times. min). Thirty nmole/kg of ANP 103-123, a possible product of NEP cleavage of ANP 103-126, produced a lesser AOC (442 mmHg .times. min) than did either of the longer peptides. The AOC responses to 100 nmole/kg of the ring-opened metabolites of ANP 99-126, 103-126 and 103-123 (105, 153, and 148 mmHg .times. min) were not different from the effect of vehicle treatment (84 mmHg .times. min). Although the natriuretic responses to increasing doses of the intact peptides did not occur in a linear fashion, Na excretion was maximally elevated by 24, 16, and 10 .mu.Eq/kg/min by 3 nmole/kg of ANP 99-126, 30 nmole/kg of ANP 103-126, and 10 nmole/kg of ANP 103-123, resp. In contrast, the natriuretic responses to 100 nmole/kg of the ring-opened metabolites of ANP 99-126, 103-126 and 103-123 (1, 5, and 2 .mu.Eq/kg/min, resp.) were not different from the response to vehicle treatment (3 .mu.Eq/kg/min). Thus, the 3 ring-opened products of NEP cleavage of ANP 99-126, 103-126, and 103-123 were inactive in conscious SHR.

ST atriopeptin peptide structure activity

IT Blood pressure
(lowering of, by atriopeptin peptides cleaved by endopeptidase, mol. structure in relation to)

IT Molecular structure-biological activity relationship
(antihypertensive, of atriopeptin peptides cleaved by endopeptidase)

IT 85637-73-6D, Atriopeptin, fragments, open ring 88898-17-3 89139-53-7, Atriopeptin-21 (rat) 90817-13-3 109881-26-7 119143-81-6 119417-98-0
RL: BIOL (Biological study)
(blood pressure lowering by, mol. structure in relation to)

L8 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1989:24282 CAPLUS

DN 110:24282

TI Synthesis and biological properties of atrial natriuretic peptide (ANP) analogs. .beta.-ANP-(7-28) and related open-chain dimers

AU Kambayashi, Yoshikazu; Kawabata, Tomoji; Shimizu, Toshikatsu; Nakamura, Masuhisa; Inouye, Ken

CS Shionogi Res. Lab., Shionogi and Co., Ltd., Osaka, 553, Japan

SO Peptide Chemistry (1988), Volume Date 1987 507-12
CODEN: PECHDP; ISSN: 0388-3698

DT Journal

LA English

CC 34-3 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 13

AB Atrial natriuretic peptide (ANP) analogs [Cys(Acm)7,23]-.alpha.-, [Cys(Acm)7,7']-.beta.'-, [Cys(Acm)7,23'-.beta.-, [Cys(Acm)23,23'-.beta.'-ANP7-28, (Acm = AcNHCH2), and .beta.-ANP7-28 were prepd. and tested for smooth muscle relaxation, natriuretic, and diuretic activities. The long-acting nature of the dimeric forms of .alpha.-ANP is not affected by removal of the N-terminal six residues, and is retained even when one of the two disulfide linkages is lost.

ST atrial natriuretic peptide analog natriuretic; diuretic atrial natriuretic peptide analog; smooth muscle relaxant atrial natriuretic peptide

IT Diuretics
Muscle relaxants
(atrial natriuretic peptide analogs as)

IT 70-18-8, Glutathione, reactions

L8 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1988:529699 CAPLUS

DN 109:129699

TI Preparation and testing of .alpha., .alpha.'-diaminosuberic acid-containing peptides as natriuretics

IN Ishida, Torao; Morikawa, Yasuri

PA Asahi Chemical Industry Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 21 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
IC ICM C07K015-12
ICS A61K037-02; C07K007-08; C07K007-10
CC 34-3 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 2
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 63027499	A2	19880205	JP 1986-171365	19860721

PRAI JP 1986-171365 19860721
OS MARPAT 109:129699
GI

AB R1NHCH(COR2)(CH2)4CH(COR4)NHR3 [I, R1, R3 = H, protecting group, (un)protected amino acid residue, (un)protected peptide residue; optionally R2R3 = bond; R2, R4 = OH, protecting group, (un)protected amino acid residue, (un)protected peptide residue], their acid addn. salts or complexes, were prepd. as diuretics. Peptide II was prepd. by the soln. method. II at 300 pmol increased urinary secretion of Na by 153 +- 21 .mu.equiv in rats.
ST diaminosuberic acid contg peptide prepn natriuretic
IT Peptides, preparation
RL: SPN (Synthetic preparation); PREP (Preparation)
L8 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1975:410896 CAPLUS
DN 83:10896
TI Synthetic modified trypsin inhibitors
IN Koenig, Wolfgang; Zwisler, Oswald; Guthoerlein, Gerhard
PA Farbwerke Hoechst A.-G., Fed. Rep. Ger.
SO Ger. Offen., 22 pp.
CODEN: GWXXBX
DT Patent
LA German
IC C07C, A61K
CC 34-3 (Synthesis of Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 7
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI DE 2344886	A1	19750403	DE 1973-2344886	19730906
DE 2344886	B2	19760812		
CH 608787	A	19790131	CH 1974-12190	19740906
US 3992529	A	19761116	US 1975-636728	19751201

PRAI DE 1973-2344886 19730906
US 1974-503066 19740904
AB Penta-N-tert-butoxycarbonyl blocked trypsin-kallikrein-inhibitor (I) was prepd. and coupled with glutamate or aspartate contg. peptides followed by deblocking to give compds. active at a rate of 1 mg modified inhibitor per 3 g trypsin. Thus, I reacted with Glu(OCMe3)-Glu(OCMe3)-OCMe3.HCl and Me3COH and DMF contg. N-ethylmorpholine and dicyclohexylcarbodiimide for 1 hr at 0.degree. and 24 hr at room temp. followed by deblocking with F3CCO2H to give trypsin-kallikrein-inhibitor-penta-(Glu-Glu-OH).
ST trypsin kallikrein inhibitor modified; peptide trypsin inhibitor
IT 35793-67-0 55943-83-4 55943-84-5

WEST Search History

DATE: Thursday, July 31, 2003

Set Name side by side	Query	Hit Count	Set Name result set
DB=USPT; PLUR=YES; OP=OR			
L22	L19 and (tripeptide or tri-peptide) and angiogen$	45	L22
L21	L19 same (tripeptide or tri-peptide)	0	L21
L20	L19 and (tripeptide or tri-peptide)	194	L20
L19	"ser asn ser" or "ser gln ser"	3046	L19
L18	L17 not (rgd or r-g-d)	17	L18
L17	L16 and (tripeptide or tri-peptide)	26	L17
DB=USPT; PLUR=NO; OP=OR			
L16	L15 not spinal	217	L16
L15	L14 not "central nervous"	270	L15
L14	L13 and (sns or sqs or tns or tqs or cns or cqs or cnc or cqc or diaminopropan$ or cns or snc or snc or snt or sqt)	709	L14
DB=USPT; PLUR=YES; OP=OR			
L13	angiogen$	5625	L13
L12	6031072 pn.	1	L12
L11	6031072 pn. and (vector$ or host)	1	L11
L10	6031072 pn. and (nucleic)	0	L10
L9	6031072 pn. and (osmo$ or pump$)	0	L9
L8	6031072 pn. and (degrad$ or biodegrad$)	1	L8
L7	6031072 pn. and ("chronic inflammation" or ocular or choroid$ or retina$ or angle or bartonellosis or osteoarthritis or rheumatoid or arthritis or phemphigoid or trachoma or osler$)	1	L7
L6	L5 and inflam$	1	L6
L5	L4 and amid$	1	L5
L4	6031072 pn. and (amid4 or hav)	1	L4
L3	L2 and hav	1	L3
L2	6169071.pn. and (amide or amid$)	1	L2
L1	6169071 and (amide or amid$)	6	L1

END OF SEARCH HISTORY